Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Mouth Neoplasms 1Melanoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

trametinib 3dabrafenib 3binimetinib 2Nivolumab 2Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1entinostat 1durvalumab 1defactinib 1copanlisib 1cobimetinib 1capivasertib 1cabiralizumab 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Midazolam × Head & Neck × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡